search: results update below


browse funds: selections are stored



recently rated:

Rated by 63
3.6

top rated funds:

Rated by 39
3.3
 

Rated by 15
3.3

Rated by 10
3.3
 

Rated by 10
3.3

Rated by 38
3.3

Rated by 38
3.3

Rated by 23
3.3

Rated by 38
3.3

Rated by 48
3.3

Rated by 39
3.3

Rated by 34
3.3

Rated by 14
3.3

Rated by 47
3.2
 

Rated by 27
3.2
 

Rated by 10
3.2
 

Rated by 31
3.2

Rated by 33
3.2

Rated by 12
3.2

Rated by 15
3.2

Rated by 10
3.2
 

Rated by 50
3.1

Rated by 14
3.1

Rated by 42
3.1

Rated by 26
3.1
 

Rated by 20
3.1

Rated by 37
3.1

Rated by 22
3.1

Rated by 14
3.1

Rated by 12
3.0

Rated by 13
3.0
 

Please take a moment and make a financial contribution to TheFunded. If we have helped you, help us with resources to further grow the both the site and our entrepreneur training program, The Founder Institute.

Abingworth Bioventures  CERTIFIED

Firm Rating:

Rated 3.2 / 5.0 by 4
Track
Record
3.7
Operating
Competence
4.0
Pitching
Efficiency
3.0
Favorable
Deal Terms
3.0
Execution
Assistance
2.5

Firm Homepage:

FIRM OVERVIEW: Large Private VC founded in 1973 based out of London, UK (Europe)

FIRM DESCRIPTION: Abingworth is an international investment group dedicated exclusively to the life sciences and healthcare sectors. We invest across all stages of company development including early and late-stage venture financing, growth equity and public companies. Founded in 1973, Abingworth has a lengthy track record of building market leading companies. Our specialist team of over 20 professionals has a broad range of skills, including scientific and business expertise as well as investment banking, recruitment and legal knowledge. These resources are made available to portfolio companies. Abingworth has funds under management of over $1.25 billion and offices in London, Menlo Park (California) and Boston.

TEAM MEMBERS: Jonathan MacQuitty, Michael Bigham, Stephen Bunting,

2
Agree
0
Disagree

Smart, Fair and Good to Work With

Fund: Abingworth Bioventures

Posted by Anonymous on 2007-11-23

PUBLIC:

Very smart group; extensive contacts in the UK and Europe; willingness to invest in early-stage companies/technologies (in the life science space); highly recommend them

PRIVATE: Members Only (51 Characters)